FDA Approves SKYRIZI — AbbVie Inc.

# FDA Approves AbbVie's SKYRIZI for Psoriasis Treatment AbbVie Inc. received FDA approval for SKYRIZI (risankizumab-rzaa), a subcutaneous IL-23 inhibitor, positioning the company to compete in the growing biologic psoriasis market against established players like Janssen and Eli Lilly. The approval expands AbbVie's dermatology portfolio and addresses a significant market opportunity in the $10+ billion global psoriasis treatment sector.